Express News | Pharma Block Sciences and Swiss Franc Alipheron jointly launched a large-scale compound library to assist drug discovery.

BreakingsMay 9 14:28

Express News | Summary of Shareholding changes on May 5.

BreakingsMay 5 22:16

Express News | Pharma Block Sciences: Shareholder Wu Xihan intends to reduce his shareholding by no more than 0.37%.

BreakingsMay 5 15:52

Pharma Block Sciences (300725): 2025 Q1 revenue growth is stable, with overseas markets contributing core performance resilience.

In Q1 2025, revenue growth is steady, while profits are under phase pressure. In 2024, the company achieved revenue of 1.689 billion yuan, a year-on-year decrease of 2.12%; net income attributable to parents was 0.22 billion yuan, an increase of 11.24% year-on-year; excluding non-recurring items.

Open Source SecuritiesApr 29 14:23

Pharma Block Sciences (300725): Orders are gradually improving, looking forward to the optimization of the company's operation margins.

Event: The company released the 2024 annual report and the first quarter report for 2025, with revenue and net income attributable to the parent company in 2024 reaching 1.689 billion yuan and 220 million yuan, respectively, down 2.12% year-on-year.

Guotou SecuritiesApr 29 14:06

Pharma Block Sciences (300725): Significant growth in CDMO Business, first time undertaking post-stage API projects for top 10 pharmaceutical companies, securities research report.

In 2024, the revenue was 1.689 billion yuan (-2.12%), net income attributable to shareholders was 0.22 billion yuan (+11.24%), and net income attributable to shareholders excluding non-recurring items was 0.173 billion yuan (-1.66%). 24Q1/Q2/

Western SecuritiesApr 28 00:00